The National Advertising Review Board (NARB) has referred Merck Animal Health to the FTC and FDA for not complying with recommendations to stop or modify its claims that Bravecto Quantum provides a full year of flea and tick protection in one dose. The panel found these claims misleading because while the product protects against multiple tick species for 12 months, protection against the lone star tick lasts only eight months. Merck agreed to add disclosures about the eight-month dosing for lone star ticks but refused to change the main annual dosing claim, leading to the referral for possible enforcement action. This case highlights the importance of clear and accurate advertising in animal health products.
The Dow Jones Industrial Average closed at a record 50,579.70, driven by optimism over progress in Iran peace talks and strong earnings reports from companies like Merck, Salesforce, and Cisco. This broad market rally included gains in healthcare, te...
Investing $200,000 evenly across three dividend ETFs—Vanguard High Dividend Yield ETF (VYM), Schwab U.S. Dividend Equity ETF (SCHD), and Invesco S&P 500 High Dividend Low Volatility ETF (SPHD)—can generate about $7,300 in annual income from roughly 6...
The Invesco Dow Jones Industrial Average Dividend ETF (DJD), launched in December 2015, tracks dividend-paying Dow stocks weighted by yield. While DJD shows value characteristics compared to the broader Dow ETF (DIA), it has underperformed DIA by 43 ...
